Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Research UK

AstraZeneca AZ

AZ and MSD win FDA priority review for Lynparza in breast cancer

Could become the first PARP inhibitor to be approved in the US for the disease

Eli Lilly HQ

Lilly gets early US approval for Ibrance rival abemaciclib

The breast cancer treatment, marketed as Verzenio, will also compete with Novartis' Kisqali

Eli Lilly HQ

Lilly’s abemaciclib data leaves potential uncertain

MONARCH 3 trial showed similar results to Pfizer’s Ibrance and Novartis’ Kisqali

- PMLiVE

Dismay as NICE turns down first-line use of AZ’s Faslodex

Says evidence isn’t convincing for use in post-menopausal women

- PMLiVE

Novartis claims EU approval for breast cancer drug Kisqali

Firm's CDK4/6 inhibitor can now challenge Pfizer's Ibrance in Europe

- PMLiVE

Biotecnol taps into Cancer Research UK network for first trial

New drug hoped to have broad activity across multiple tumour types

Roche Basel Switzerland

Roche trumpets APHINITY data, but did it hit the mark?

Results raise questions about benefit of combining Herceptin with Perjeta

- PMLiVE

AZ’s Lynparza shows PARP inhibitor potential in breast cancer

Findings were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago

Eli Lilly HQ

Lilly adds to data backing breast cancer candidate abemaciclib

US pharma giant’s drug achieves PFS rate of 16.4 months

- PMLiVE

FDA panel backs Puma’s breast cancer drug, with reservations

Side effects concerns could see medicines limited

- PMLiVE

Activists torpedo Immunomedics deal with Seattle Genetics

venBio says deal will enrich CEO at shareholders' expense

- PMLiVE

ghg London wins Cancer Research UK account

Will provide marketing support to the charity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links